Edgemont Pharmaceuticals engages in developing drug products... Read more
Edgemont Pharmaceuticals, LLC CEO: Douglas A. Saltel

CEO

Douglas A. Saltel

CEO Approval Rating

70/100

Est. Annual Revenue
$25-100M
Agree?
Est. Employees
1-25
Agree?
Funding
$5M

News

Jul 30, 2017
BioPortfolio
Edgemont Pharmaceuticals: Edgemont Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27072017 Prices from USD $250
Feb 05, 2017
BioPortfolio
Edgemont Pharmaceuticals: Edgemont Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250
Jun 23, 2015
BUSINESS WIRE
Press Release: Edgemont Pharmaceuticals : Research and Markets: Menopausal Hot Flashes Therapeutics Pipeline Review, H1 2015 - 6 Companies & 11 Drug Profiles
Jun 10, 2015
PR-INSIDE.COM
Press Release: Edgemont Pharmaceuticals : Market Report, "Edgemont Pharmaceuticals, LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile", published
Jun 05, 2015
BUSINESS WIRE
Press Release: Edgemont Pharmaceuticals : Research and Markets: Global Treatment Resistant Depression Therapeutics Pipeline Report 2015 - 7 Companies & 12 Drug Profiles
Jun 05, 2015
BUSINESS WIRE
Press Release: Edgemont Pharmaceuticals : Research and Markets: General Anxiety Disorder Therapeutics Pipeline Review, H1 2015 Featuring Edgemont Pharmaceuticals, LLC, H. Lundbeck A/S & Pfizer Inc.
May 06, 2015
BIOSPACE
Edgemont Pharmaceuticals: <b>Oxford Finance</b> Provides $5 Million Term Loan Expansion To Edgemont Pharmaceuticals, LLC.
May 01, 2015
FINSMEs
Edgemont Pharmaceuticals: Edgemont Pharamaceuticals Receives $5M Loan from Oxford Finance
May 01, 2015
PR NEWSWIRE
Press Release: Edgemont Pharmaceuticals : Oxford Finance Provides $5 Million Term Loan Expansion to Edgemont Pharmaceuticals
Dec 03, 2014
BUSINESS WIRE
Press Release: Edgemont Pharmaceuticals : Research and Markets: General Anxiety Disorder - Pipeline Review, H2 2014

Trending Companies